SCHEMBL22409603

SCHEMBL22409603

CC1(C)OC(=O)C(=CC=Cc2cncc3ccccc23)C(=O)O1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APP P05067 1/20 0.40
▸ AURKA O14965 2/20 0.40
▸ KDR P35968 2/20 0.40
▸ ERBB2 P04626 1/20 0.40
▸ SRD5A1 P18405 1/20 0.38
▸ SRD5A2 P31213 1/20 0.38
▸ ALDH1A1 P00352 9/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ PIK3CD O00329 1/20 0.34
▸ PIK3CA P42336 1/20 0.34
▸ CYP11B1 P15538 2/20 0.33
▸ CYP11B2 P19099 2/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ TDP1 Q9NUW8 2/20 0.33
▸ PARP1 P09874 1/20 0.33
▸ PRKCI P41743 1/20 0.33
▸ PDE4B Q07343 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22423782 1.00 APP (0.40) APPAURKAKDRERBB2SRD5A1
SCHEMBL22409638 0.89 AURKA (0.39) APPAURKAKDRERBB2SRD5A1
SCHEMBL22409605 0.86 KDM4E (0.40) AURKAKDRERBB2SRD5A1SRD5A2
SCHEMBL22423748 0.83 APP (0.44) APPALDH1A1KDM4EMEN1LMNA
SCHEMBL22409619 0.83 APP (0.44) APPALDH1A1KDM4EMEN1LMNA
SCHEMBL22409617 0.74 ALDH1A1 (0.46) APPALDH1A1CYP1A2CYP2C9PIK3CA
SCHEMBL6655162 0.74 AURKA (0.45) AURKAKDRERBB2SRD5A1SRD5A2
SCHEMBL6655165 0.74 AURKA (0.45) AURKAKDRERBB2SRD5A1SRD5A2
SCHEMBL22409595 0.73 MTNR1A (0.38) KDM4EMEN1LMNAPOLBMAPT
SCHEMBL22409622 0.72 ALDH1A1 (0.47) APPALDH1A1CYP1A2CYP2C9SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11161823-B2 Anticancer 1,3-dioxane-4,6-dione derivatives and method of combinatorial synthesis thereof NATIONAL GUARD HEALTH AFFAIRS (SA) 2021-11-02 — — US disclosed
US-20200290975-A1 ANTICANCER 1,3-DIOXANE-4,6-DIONE DERIVATIVES AND METHOD OF COMBINATORIAL SYNTHESIS THEREOF NATIONAL GUARD HEALTH AFFAIRS (SA) 2020-09-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11161823-B2 Anticancer 1,3-dioxane-4,6-dione derivatives and method of combinatorial synthesis thereof PDK1, PDHA1, PDHA2 APP 4872/4885AURKA 176/4885KDR 477/4885
US-20200290975-A1 ANTICANCER 1,3-DIOXANE-4,6-DIONE DERIVATIVES AND METHOD OF COMBINATORIAL SYNTHESIS THEREOF PDK1, PDHA1, PDHA2 APP 4872/4885AURKA 176/4885KDR 477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback